Sequential Therapy versus Quadruple Therapy for Helicobacter pylori Eradicatio

Phase 3

• Conditions: Helicobacter pylori.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20171230038142N20
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 174

Inclusion Criteria

Age 18 years and older
Ulcerative peptic ulcer disease based on upper gastrointestinal endoscopy

Exclusion Criteria

Having any of the following diseases: MALT, Zollinger-Ellison syndrome, various types of gastrointestinal cancers, liver or kidney diseases, other infections that require antibiotics, immunodeficiency diseases.
History of upper gastrointestinal surgery
History of Helicobacter pylori eradication or history of PPI use of antibiotics or probiotics (artificial or natural) during the past 4 weeks

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of complications. Timepoint: Days 15 and 30 after starting treatment. Method of measurement: Question from the patient.;Duration of treatment. Timepoint: After treatment. Method of measurement: Counting the days of receiving treatment.;Helicobacter pylori eradication rate. Timepoint: After treatment. Method of measurement: Stool test.;Patient symptoms. Timepoint: Before and after treatment. Method of measurement: SF-LDQ questionnaire.